Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Pfizer (PFE) currently faces dual concerns in the market about its growth prospects and dividend safety, causing its valuation to remain low. However, from the perspective of financial ...

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...

Key TakeawaysPfizer yields about 6% and Bristol Myers about 4%, and each has more than $22 billion of revenue from drugs ...

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial ...

Pfizer has been going through a period of transition.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pfizer (NYSE:PFE) will release its quarterly earnings report on Tuesday, 2026-02-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Pfizer to report an earnings ...

Pfizer agreed to share a portion of its net increased revenue from charging higher prices abroad with US Department of Health and Human Services ...